Mary Scoviak, Managing Editor

Minimally invasive method outperformed tape stripping in a recent study.

Suneel Chilukuri, MD, director of Cosmetic Surgery at Refresh Dermatology in Houston, Texas, gives keys pearls on fillers and neuromodulators and what innovation is heading for the industry.

Suneel Chilukuri, MD, director of Cosmetic Surgery at Refresh Dermatology in Houston, Texas, explores potential international technology that may transform the injectable space.

Suneel Chilukuri, MD, director of Cosmetic Surgery at Refresh Dermatology in Houston, Texas, discusses what to expect from Maui Derm NP+PA Summer 2022 Conference.

Infusion centers are very much affected by legislative action on drugs. An expert offers insights into how best to navigate the situation.

Darrell S. Rigel, MD, MS, FAAD, answers the question of what is up coming in the world of dermatology in the way of precision medicine.

Darrell S. Rigel, MD, MS, delves into the power and potential of precision medicine in diagnosis, prognosis and therapy selection.

Will drinking caffeinated coffee reduce skin cancer risk? Is gene expression profiling set to become mainstream testing for melanoma? See what Darrell S. Rigel, MD, MS, FAAD, has to say.

Darrell S. Rigel highlights what to expect for the 2022 Fall Clinical Dermatology Conference for PAs & NPs happening June 3 to 5 in Scottsdale, Arizona.

The AAD recently added topical tirbanibulin (Klisyri: Almirall) to its list of recommended therapies for treating AK.

Learn to discern the best pain-mitigation strategies for each patient, based on research and personal experience.

Matthew Zirwas, MD, shares his step-by-step pearls for quelling this pruritic skin condition.

A poster presented at the 2022 American College of Mohs Surgery Annual Meeting not only suggested a link between multiple myeloma and a heightened rate of melanoma, but also demonstrated potential for higher overall mortality rates.

Dermatology has enjoyed one of the lowest litigation rates among medical specialties, but recent findings presented at the 2022 American College of Mohs Surgery Annual Meeting caution that mounting risks relating to procedural dermatology and cutaneous oncology could change that.

Is rosacea being confused with acne? Are physicians treating the their patients with the patient's expectations in mind? Questions like these are more are answered by Adebola Dele-Michael, MD.

Two experts offer a step-by-step guide to creating an effective multidisciplinary treatment team.

A clinician updates the conventional wisdom on acne’s variations in patients of color, offering pearls from her practice and practical takeaways from recent research.

In a presentation at New Wave Dermatology Conference, Matthew Zirwas, MD, delved into why atopic dermatitis (AD) should be the first condition that comes to mind when an adult patient presents with dermatitis, why presentation is different in pediatric and adult patients, and why treating AD is about more than quality of life.

Matthew J. Zirwas, MD, detailed best-practice tactics for addressing this category of itch in a presentation at New Wave Dermatology Conference.

At the Society of Dermatology Nurse Practitioners Annual Symposium, Susan Kendig, WHNP, JD, shared insights to lead to better outcomes and decreased liability throughout the patient journey, from diagnosis and follow-up to EMRs.

Susan Kendig, WHNP, JD, detailed how nurse practitioners working in telehealth can limit their liability and protect their practices in her session on legal issues.

At the opening session of the Society of Dermatology Nurse Practitioners Annual Symposium, Kathleen Haycraft, DNP, FNP-BC, DCNP, FAANP, delved into the revolutionary and evolutionary advances shaping dermatology in 2022.

At the opening session of the Society of Dermatology Nurse Practitioners Annual Symposium, Kathleen Haycraft, DNP, FNP-BC, DCNP, FAANP, shared insights into the state of the profession and what’s ahead.

Now, with an increasing emphasis on multidisciplinary tumor review boards and heightened expectations for pipeline drugs, physicians have new tools for building treatment plans that may push response rates beyond the 30% range.

Experts take a closer look at when to watch, and what to watch for in patients on JAK inhibitors.

In this fourth part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, talks about what to look forward to in treatment and clinical trials of merkel cell carcinoma (MCC).

In this third part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, highlights the in practice experiences in using circulating tumor DNA for merkel cell carcinoma (MCC).

In this second part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the data behind the clinical trials on using circulating tumor DNA for merkel cell carcinoma (MCC). She expands on her talk from the 2022 American Academy of Dermatology Annual Meeting.

Christopher Bunick, MD, PhD, offered pointers on how to address the physical and mental aspects of this complex disease in this exclusive interview in conjunction with the American Academy of Dermatology 2022 Annual Meeting.

In this first part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the science behind her presentation on "The Utility of Circulating Tumor DNA for Detecting Clinically Evident and Occult Merkel Cell Carcinoma." This was presented at the 2022 American Academy of Dermatology Annual Meeting.